Visugromab (Powder)

Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) [1].

Product Specifications

CAS Number

[2556646-63-8]

Product Name Alternative

CLT-002 (Powder)

UNSPSC

12352203

Target

PD-1/PD-L1; TGF-beta/Smad

Related Pathways

Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Cancer

Smiles

[Visugromab(Powder)]

References & Citations

[1]Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC) : A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER) [J]. 2023.|[2]Melero I, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan;637 (8048) :1218-1227.